Skip to content

The Effect of Nitrate on Brown Fat

The Effect of Inorganic Nitrate Supplementation on Brown Fat Activation and Quantity in People With Type 2 Diabetes Mellitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05342012
Enrollment
13
Registered
2022-04-22
Start date
2022-06-30
Completion date
2023-07-31
Last updated
2023-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Beetroot, Brown Adipose Tissue, Infrared spectrometry, Magnetic Resonance Imaging, Nitrates, Type II Diabetes Mellitus

Brief summary

Type 2 diabetes mellitus (T2DM) is a metabolic condition characterized by chronic hyperglycemia and progressive insulin resistance, which progressively lead to macro- and microvascular damage. With the number of people with T2DM continuing to rise, this pandemic is expected to reach 700 million people by 2045, such that the costs associated with its clinical management are likely to become unsustainable. Therefore, identifying cost effective alternative interventions is imperative. Diets rich in fruits and vegetables are well known to have cardiovascular benefits and reduce the risk of getting T2DM. The beneficial effects of vegetables on cardiovascular outcomes are particularly effective in green leafy vegetables and beetroot. This may in part be due to a high concentration of inorganic nitrate, and its beneficial effects on cardiovascular health due to its effect on nitric oxide (NO•). Increased dietary nitrate intake elevates cyclic guanosine monophosphate \[(cGMP)\]. Importantly, cGMP has also been shown to increase brown fat expression by 'beiging' WAT in mice through an NO• dependent process. Recent developments in the ability to non-invasively measure BAT activation using magnetic resonance imaging (MRI) and infrared thermography (ITR) has opened the possibility to study the effects of nitrate on BAT activation in man. BAT depots in humans with T2DM have been identified using MRI but not yet with the more easily accessible technique of IRT. It is hypothesised that nitrate can increase BAT activation and quantity in people with T2DM.

Detailed description

Dietary inorganic nitrate is converted in a reversible, stepwise reaction to nitrite via bacteria on the dorsum of the tongue. Subsequently, small quantities of NO• are produced in the stomach. The remaining nitrite is then absorbed into the circulation where it acts as a storage pool for subsequent NO• production. Production of NO• from nitrite reduction is expedited in hypoxaemia, a phenomenon observed in the vasculature of white adipose tissue (WAT). WAT is primarily an energy store, whereas brown adipose tissue (BAT) is a metabolically active tissue. BAT is responsible for \ 5% of basal metabolic rate and \ 15% of total energy expenditure, equating to \ 40 g of BAT per day and is used in non-shivering thermogenesis. BAT is used for heat production and is stimulated by cold environments and or diet to cause thermogenesis. To produce heat during cold exposure, uncoupling protein (UCP)-1, an inner mitochondrial protein, is upregulated in BAT ultimately uncoupling the mitochondrial proton gradient, making the cell less energy efficient. Inorganic nitrate supplementation has also been shown to increase UCP-1 expression in BAT.

Interventions

DIETARY_SUPPLEMENTConcentrated beetroot juice

Acute and chronic supplementation of beetroot juice.

(Nitrate depleted beetroot juice

Sponsors

University of Portsmouth
CollaboratorOTHER
Institute of Bioengineering and Bioimaging (IBB)
CollaboratorOTHER_GOV
Loughborough University
CollaboratorOTHER
Bournemouth University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Double blind randomised control trial. Supplements will be dispensed by a member of the research team.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males or women with Type 2 Diabetes Mellitus

Exclusion criteria

* Individuals with a BMI over 30 * Individuals with severe claustrophobia (this would make imaging the BAT less reliable) * Current smokers (or those that have smoked within 3 months) * Proton pump inhibitors or phosphodiesterase inhibitor users, as these may affect \[cGMP\]. Half life of this drug is short. Participants can choose to not use this if they wish to participate. * Individuals with any other serious medical condition which would interfere with data interpretation or safety will be excluded from participation. * Unable to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
MRI Imaging of Supraclavicular BATMRI on day 14 (Visit 2) before 60 minutes of cold exposure, following 14-days beetroot/placebo supplementation with 7-day washout between crossover.High-resolution 3-dimensional T1-weighted imaging will be acquired using repetition time, echo time and field of view. All imaging sequences will have anatomical coverage of the neck, supraclavicular region and the apices of the lung.
A 3D multi-point Dixon sequence will be utilized for the water-fat imaging.At start of MRI Imaging of Supraclavicular BATA 3D multi-point Dixon sequence will be utilized for the water-fat imaging.
Pixel wise quantification of fat fraction will be performed from fat and water maps.At time of MRI ImagingPixel wise quantification of fat fraction will be performed from fat and water maps.

Secondary

MeasureTime frameDescription
IRT Imaging of Supraclavicular BATIRT on day 14 (Visit 2) and day 35 (visit 3), before and after 60 minutes of cold water immersion, following 14-days beetroot/placebo supplementation with 7-day washout between crossover.Bilaterally, two regions will be analysed for skin temperature from thermal images using infrared cameras: 1) the skin area overlaying BAT in the SCV fossae on the left and right sides, and; 2) the sternal area considered as a control.
Biomarkers - cGMPBlood sampling on day 14 (Visit 2) and day 35 (visit 3) following 14-days beetroot/placebo supplementation with 7-day washout between crossover.Quantified using a Sievers nitric oxide analyser
Biomarkers - NitrateBlood sampling on day 14 (Visit 2) and day 35 (visit 3) following 14-days beetroot/placebo supplementation with 7-day washout between crossover.Quantified using a Sievers nitric oxide analyser
Biomarkers - NitriteBlood sampling on day 14 (Visit 2) and day 35 (visit 3) following 14-days beetroot/placebo supplementation with 7-day washout between crossover.Quantified using a Sievers nitric oxide analyser

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026